Damora Therapeutics, Inc. has grown revenue 81% a year over three years and 65% a year over five. Revenue growth, 3-year annual rate: +81% (Biotechnology median +17%). Revenue growth, 5-year rate: +65%, growth has picked up over the last three years. Years of annual history on file: 7, FY2019 to FY2025, as filed.

DMRADamora Therapeutics, Inc.

Healthcare

$21.12+636% 1Y

$21.12

$3.0052 weeks$34.14

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +1541% year on year, but earnings down −157% year on year and operating margin narrowing (−3357.6 points).

1 good, 2 to watch

Revenue trend+1541% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Earnings trend−157% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−3357.6 points operating

Trailing-twelve-month operating margin, -7382.4% now against -4024.8% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is DMRA growing?

Damora Therapeutics, Inc. has grown revenue 81% a year over three years and 65% a year over five.

+81%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +65%
Revenue growth, 5-year rate · +81% over three · growth has picked up over the last three years
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed

Details›